CA2337349A1 - Compositions ophtalmiques destinees au traitement de l'hypertension oculaire - Google Patents
Compositions ophtalmiques destinees au traitement de l'hypertension oculaire Download PDFInfo
- Publication number
- CA2337349A1 CA2337349A1 CA002337349A CA2337349A CA2337349A1 CA 2337349 A1 CA2337349 A1 CA 2337349A1 CA 002337349 A CA002337349 A CA 002337349A CA 2337349 A CA2337349 A CA 2337349A CA 2337349 A1 CA2337349 A1 CA 2337349A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- prostaglandin
- ophthalmologically acceptable
- carbonic anhydrase
- dihydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des combinaisons d'une prostaglandine, d'un dérivé de prostaglandine, d'un lipide hypotenseur dérivé d'une prostaglandine ou d'un dérivé de prostaglandine ou d'un sel ophtalmologiquement acceptable de ceux-ci et d'un inhibiteur topique de l'anhydrase carbonique ou d'un sel ophtalmologiquement acceptable de celui-ci, qui sont utilisées en particulier dans le traitement de l'hypertension oculaire et du glaucome. Ces combinaisons sont caractérisées par un effet amélioré et des effets secondaires réduits.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11995198A | 1998-07-21 | 1998-07-21 | |
US09/119,951 | 1998-07-21 | ||
PCT/US1999/016374 WO2000004899A1 (fr) | 1998-07-21 | 1999-07-20 | Compositions ophtalmiques destinees au traitement de l'hypertension oculaire |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2337349A1 true CA2337349A1 (fr) | 2000-02-03 |
Family
ID=22387375
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002337349A Abandoned CA2337349A1 (fr) | 1998-07-21 | 1999-07-20 | Compositions ophtalmiques destinees au traitement de l'hypertension oculaire |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1100491A1 (fr) |
JP (1) | JP2002521333A (fr) |
AU (1) | AU5114499A (fr) |
CA (1) | CA2337349A1 (fr) |
WO (1) | WO2000004899A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2754712B1 (fr) * | 1996-10-17 | 1999-09-03 | Merck Sharp Dohme Chibret Lab | Compositions ophtalmiques |
WO2000051980A1 (fr) | 1999-03-05 | 2000-09-08 | The Procter & Gamble Company | Analogues de prostaglandines c16 fp selectives insaturees |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
AU2001261360A1 (en) * | 2000-05-10 | 2001-11-20 | Alcon, Inc. | R-eliprodil for treating glaucoma |
JP2004528369A (ja) * | 2001-05-03 | 2004-09-16 | アラーガン、インコーポレイテッド | 向上した薬物動態特性を有する組成物 |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
EP1797888A4 (fr) | 2004-09-28 | 2009-12-16 | Senju Pharma Co | Composition ophtalmique contenant de la gomme xanthane et un acide amine |
US7998942B2 (en) | 2005-07-11 | 2011-08-16 | Senju Pharamaceutical Co., Ltd. | Eye drop preparation comprising xanthan gum and terpenoid |
GB2423711B (en) * | 2005-10-24 | 2007-02-14 | Fortune Apex Dev Ltd | Method for preparing a pharmaceutical composition with enhanced mucoadhesion |
KR101381035B1 (ko) | 2006-03-23 | 2014-04-04 | 센주 세이야꾸 가부시키가이샤 | 잔탄검 및 글루코스를 포함하는 안약 조성물 |
US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU674038B2 (en) * | 1992-10-13 | 1996-12-05 | Alcon Laboratories, Inc. | Combinations of prostaglandins and clonidine derivatives for the treatment of glaucoma |
-
1999
- 1999-07-20 EP EP99935726A patent/EP1100491A1/fr not_active Withdrawn
- 1999-07-20 AU AU51144/99A patent/AU5114499A/en not_active Abandoned
- 1999-07-20 WO PCT/US1999/016374 patent/WO2000004899A1/fr not_active Application Discontinuation
- 1999-07-20 CA CA002337349A patent/CA2337349A1/fr not_active Abandoned
- 1999-07-20 JP JP2000560892A patent/JP2002521333A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2002521333A (ja) | 2002-07-16 |
WO2000004899A1 (fr) | 2000-02-03 |
AU5114499A (en) | 2000-02-14 |
EP1100491A1 (fr) | 2001-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2337399A1 (fr) | Compositions ophtalmiques pour le traitement de l'hypertension oculaire | |
CA2337349A1 (fr) | Compositions ophtalmiques destinees au traitement de l'hypertension oculaire | |
US20120040994A1 (en) | THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDIN | |
EP0580268B1 (fr) | Agents oculaires hypotenseurs | |
JP4314433B2 (ja) | Rhoキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤 | |
CA2291777A1 (fr) | Compositions ophtalmiques pour traitement de l'hypertension oculaire | |
JP4482726B2 (ja) | Rhoキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤 | |
US20020094981A1 (en) | Ophthalmic compositions for treating ocular hypertension | |
US6545045B1 (en) | Prostaglandin E agonists for treatment of glaucoma | |
EP1267847B1 (fr) | Agonistes de 5ht 2 permettant de controler la pression intra-oculaire elevee et de traiter le glaucome | |
CA2146006C (fr) | Utilisation de derives de l'ergoline dans le traitement du glaucome | |
EP0509752B1 (fr) | Compositions ophtalmiques contenant des combinaisons d'un inhibiteur d'anhydrase carbonique et d'un antagoniste bêta-adrénergique | |
US6232343B1 (en) | Ophthalmic preparations | |
JP7346305B2 (ja) | ピリジルアミノ酢酸化合物を含有する医薬製剤 | |
US6316443B1 (en) | Ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a β-adrenergic antagonist | |
US5405846A (en) | Treatment of ocular hypertension with a synergistic combination | |
JP4300347B2 (ja) | ブナゾシンとプロスタグランジン類からなる緑内障治療剤 | |
US20060211700A1 (en) | (R)-8,9-dichloro-2,3,4,4a-tetrahydro-1H,6H-pyrazino[1,2-a]quinoxalin-5-one for controlling IOP and treating glaucoma | |
US20050043412A1 (en) | Remedies for glaucoma comprising bunazosin and prostaglandins | |
CN111479567B (zh) | 包含FP激动剂和β-阻断剂的青光眼的治疗剂 | |
US6160013A (en) | 14-aza prostaglandins for the treatment of glaucoma and ocular hypertension | |
US6927233B1 (en) | 5ht2 agonists for controlling IOP and treating glaucoma | |
EP1049466B1 (fr) | Technique visant a accroitre la tension en oxygene du nerf optique et de la retine | |
WO2005023258A1 (fr) | Compositions contenant des derives de benzo(g)quinoline et des derives de prostaglandine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |